Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP 92 Days Sales Outstanding is 74.98 as of Mar. 2026, which is 20% below its 10-year median of 93.22. GuruFocus rates ASX:AFP with a GF Score™ of 92/100 and a GF Value™ of A$3.40 (Fairly Valued). The stock has 4 warning signs investors should review. Among 948 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 56.65% on this metric.
The historical rank and industry rank for AFT Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:
ASX:AFP'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 79.5 Med: 93.22 Max: 117.63
Current: 79.5
During the past 11 years, AFT Pharmaceuticals's highest Days Sales Outstanding was 117.63. The lowest was 79.50. And the median was 93.22.
ASX:AFP's Days Sales Outstanding is ranked worse than 56.65% of 948
companies
in the Drug Manufacturers industry
Industry Median: 71.99
vs ASX:AFP: 79.50
AFT Pharmaceuticals's Days Sales Outstanding
increased
from Mar. 2025 (62.44) to Mar. 2026 (74.98).
AFT Pharmaceuticals (ASX:AFP) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
AFT Pharmaceuticals Days Sales Outstanding Related Terms
AFT Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AFP vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Days Sales Outstanding falls into.
AFT Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (ASX:AFP) has a Days Sales Outstanding of 74.98 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AFT Pharmaceuticals and its competitors. This is 20% below median its historical median of 93.22. Over the past decade, AFT Pharmaceuticals' Days Sales Outstanding has ranged from 79.50 to 117.63. According to the industry distribution chart, AFT Pharmaceuticals ranks #537 out of 948 companies in the Drug Manufacturers industry, placing it in the top 56.6%.
Is AFT Pharmaceuticals' Days Sales Outstanding too high?
AFT Pharmaceuticals' current Days Sales Outstanding of 74.98 is 20% below median its 10-year median of 93.22. Over the past 10 years, this metric has ranged from a low of 79.50 to a high of 117.63. The Drug Manufacturers industry median Days Sales Outstanding is 71.99. AFT Pharmaceuticals' value of 74.98 is 4.2% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #537 out of 948 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #537 out of 948 companies for Days Sales Outstanding. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 71.99. AFT Pharmaceuticals' value of 74.98 is 4.2% above this benchmark. Historically, AFT Pharmaceuticals' own Days Sales Outstanding has ranged from 79.50 to 117.63 over the past decade. While the company's 10-year median is 93.22 vs. the industry median of 71.99, AFT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.99, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Days Sales Outstanding of 74.98 is 4.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Days Sales Outstanding is 74.98, which is 20% below median its own 10-year median of 93.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.40, compared to a current price of A$3.29 — trading 3.2% below its estimated fair value. The current Days Sales Outstanding is 74.98, which is 20% below median its 10-year median of 93.22 and 4.2% above the Drug Manufacturers industry median of 71.99. AFT Pharmaceuticals' overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Days Sales Outstanding is 74.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of A$3.29 is trading 3.2% below its estimated GF Value™ of A$3.40.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
Days Sales Outstanding: 74.98 (20% below median its 10-year median of 93.22)
GF Value™: A$3.40 vs. price of A$3.29 (3.2% below fair value)
Industry Position: 4.2% above the Drug Manufacturers median (#537 of 948)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
92GF Score
Get the complete analysis for ASX:AFP
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
